444 related articles for article (PubMed ID: 26183715)
21. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin.
Liu T; Peng H; Zhang M; Deng Y; Wu Z
Eur J Pharmacol; 2010 Sep; 641(1):15-22. PubMed ID: 20483353
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the signal transducer and activator of transcription 3 signaling pathway by Qianliening capsules suppresses the growth and induces the apoptosis of human prostate cells.
Lin J; Zhou J; Zhong X; Hong Z; Peng J
Mol Med Rep; 2015 Mar; 11(3):2207-14. PubMed ID: 25394909
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
[TBL] [Abstract][Full Text] [Related]
24. Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH‑SY5Y human neuroblastoma cells.
Zheng Q; Liu Y; Liu W; Ma F; Zhou Y; Chen M; Chang J; Wang Y; Yang G; He G
Mol Med Rep; 2014 Jul; 10(1):89-94. PubMed ID: 24789581
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
27. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
28. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
29. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
31. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer.
Liu T; Zhang M; Zhang H; Sun C; Yang X; Deng Y; Ji W
Eur J Pharmacol; 2008 Jun; 587(1-3):78-84. PubMed ID: 18442812
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
33. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
34. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
35. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
36. [Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells].
Liu T; Zhang M; Deng Y; Zhang H; Sun C; Yang X; Ji W
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 May; 22(9):403-7. PubMed ID: 18652313
[TBL] [Abstract][Full Text] [Related]
37. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
38. Cucurbitacin B regulates lung cancer cell proliferation and apoptosis
Liu JH; Li C; Cao L; Zhang CH; Zhang ZH
Pharm Biol; 2022 Dec; 60(1):154-162. PubMed ID: 34967707
[TBL] [Abstract][Full Text] [Related]
39. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
40. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]